Alessandra Iacovelli1, Martina Spaziante2, Samir Al Moghazi1, Alessandra Giordano1, Giancarlo Ceccarelli1, Mario Venditti3. 1. Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy. 2. Department of Clinical Medicine, "Sapienza" University of Rome, Rome, Italy. 3. Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy. mario.venditti@uniroma1.it.
Abstract
INTRODUCTION: The emergence of carbapenemase-producing Klebsiella pneumonia (KPC-Kp) has become a significant problem in terms of public health and clinical outcome in many hospitals in Southern Europe. Treatment options are usually limited and effective treatment of infections caused by these pathogens is a considerable challenge for clinicians. Ceftazidime-avibactam has been recently approved for the treatment of difficult-to-treat infections due to aerobic Gram-negative organisms in patients with limited treatment options. CASE REPORT: We reported the first case of KPC-Kp septic thrombophlebitis and right atrial endocarditis associated with metastatic lung abscesses successfully treated with a prolonged ceftazidime/avibactam plus ertapenem treatment course, suggesting that this combination therapy could be safe and effective for serious Gram-negative infections. Interestingly, we also observed an apparent discrepancy between clinical and microbiological courses: the patient became rapidly afebrile; hemodynamically stable and his procalcitonin levels showed a prompt decreasing trend. Nevertheless, blood cultures remained persistently positive for a prolonged period. CONCLUSION: In conclusion, ceftazidime-avibactam plus ertapenem was a safe and effective therapy of serious endovascular infection due to KPC-Kp. Moreover, in this setting, follow-up blood cultures might represent an irreplaceable tool to guide the therapy.
INTRODUCTION: The emergence of carbapenemase-producing Klebsiella pneumonia (KPC-Kp) has become a significant problem in terms of public health and clinical outcome in many hospitals in Southern Europe. Treatment options are usually limited and effective treatment of infections caused by these pathogens is a considerable challenge for clinicians. Ceftazidime-avibactam has been recently approved for the treatment of difficult-to-treat infections due to aerobic Gram-negative organisms in patients with limited treatment options. CASE REPORT: We reported the first case of KPC-Kp septic thrombophlebitis and right atrial endocarditis associated with metastatic lung abscesses successfully treated with a prolonged ceftazidime/avibactam plus ertapenem treatment course, suggesting that this combination therapy could be safe and effective for serious Gram-negative infections. Interestingly, we also observed an apparent discrepancy between clinical and microbiological courses: the patient became rapidly afebrile; hemodynamically stable and his procalcitonin levels showed a prompt decreasing trend. Nevertheless, blood cultures remained persistently positive for a prolonged period. CONCLUSION: In conclusion, ceftazidime-avibactam plus ertapenem was a safe and effective therapy of serious endovascular infection due to KPC-Kp. Moreover, in this setting, follow-up blood cultures might represent an irreplaceable tool to guide the therapy.
Authors: S Leone; V Ravasio; E Durante-Mangoni; M Crapis; G Carosi; P G Scotton; N Barzaghi; M Falcone; P Chinello; M B Pasticci; P Grossi; R Utili; P Viale; M Rizzi; F Suter Journal: Infection Date: 2012-06-19 Impact factor: 3.553
Authors: Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Brian A Potoski; Rachel V Marini; Yohei Doi; Barry N Kreiswirth; Cornelius J Clancy Journal: Antimicrob Agents Chemother Date: 2017-07-25 Impact factor: 5.191
Authors: Marco Falcone; Giusy Tiseo; Emanuele Durante-Mangoni; Veronica Ravasio; Francesco Barbaro; Maria Paola Ursi; Maria Bruna Pasticci; Matteo Bassetti; Paolo Grossi; Mario Venditti; Marco Rizzi Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191
Authors: David R Murdoch; G Ralph Corey; Bruno Hoen; José M Miró; Vance G Fowler; Arnold S Bayer; Adolf W Karchmer; Lars Olaison; Paul A Pappas; Philippe Moreillon; Stephen T Chambers; Vivian H Chu; Vicenç Falcó; David J Holland; Philip Jones; John L Klein; Nigel J Raymond; Kerry M Read; Marie Francoise Tripodi; Riccardo Utili; Andrew Wang; Christopher W Woods; Christopher H Cabell Journal: Arch Intern Med Date: 2009-03-09
Authors: Susan Morpeth; David Murdoch; Christopher H Cabell; Adolf W Karchmer; Paul Pappas; Donald Levine; Francisco Nacinovich; Pierre Tattevin; Núria Fernández-Hidalgo; Stuart Dickerman; Emilio Bouza; Ana del Río; Tatjana Lejko-Zupanc; Auristela de Oliveira Ramos; Diana Iarussi; John Klein; Catherine Chirouze; Roger Bedimo; G Ralph Corey; Vance G Fowler Journal: Ann Intern Med Date: 2007-12-18 Impact factor: 25.391
Authors: Majed F Alghoribi; Moayad Alqurashi; Liliane Okdah; Bassam Alalwan; Yahya S AlHebaishi; Abdulmajeed Almalki; Maha A Alzayer; Abdulrahman A Alswaji; Michel Doumith; Mazin Barry Journal: Sci Rep Date: 2021-05-06 Impact factor: 4.379
Authors: Alessandra Oliva; Ambrogio Curtolo; Lorenzo Volpicelli; Francesco Cogliati Dezza; Massimiliano De Angelis; Sara Cairoli; Donatella Dell'Utri; Bianca Maria Goffredo; Giammarco Raponi; Mario Venditti Journal: Antibiotics (Basel) Date: 2021-06-27